Meeting News CoverageVideo

VIDEO: Drugs, devices bring ‘new era’ of glaucoma care

ATLANTA – “A new era of glaucoma management has arrived,” J. James Thimons, OD, said here at SECO. Thimons discussed how Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) relaxes the trabeculum and may provide some form of trabecular regeneration. He said Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) has an additive effect to latanoprost acid by increasing vascular permeability and flow in and around the trabecular meshwork.

Thimons explained how these two new drugs, as well as new micro-invasive glaucoma surgery procedures, fit into the glaucoma patient care regimen.

ATLANTA – “A new era of glaucoma management has arrived,” J. James Thimons, OD, said here at SECO. Thimons discussed how Rhopressa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) relaxes the trabeculum and may provide some form of trabecular regeneration. He said Vyzulta (latanoprostene bunod ophthalmic solution 0.024%, Bausch + Lomb) has an additive effect to latanoprost acid by increasing vascular permeability and flow in and around the trabecular meshwork.

Thimons explained how these two new drugs, as well as new micro-invasive glaucoma surgery procedures, fit into the glaucoma patient care regimen.

    See more from SECO